| Literature DB >> 28923349 |
Yoon Jeong Nam1, Arum Kim1, Min Sung Lee2, Dong Suep Sohn3, Chung Soo Lee4.
Abstract
Changes in the KATP channel activity have been shown to regulate inflammation and immune responses. Using human keratinocytes, we investigated the effect of KATP channel inhibition on inflammatory mediator production in relation to the Toll like receptor-2-mediated-Akt, mTOR and NF-κB pathways, as well as JNK and p38-MAPK, which regulate the transcription genes involved in immune and inflammatory responses. 5-Hydroxydecanoate (a selective KATP channel blocker), glibenclamide (a cell surface and mitochondrial KATP channel inhibitor), the Akt inhibitor, rapamycin, Bay 11-7085 and N-acetylcysteine reduced the lipoteichoic acid- or peptidoglycan-induced production of cytokines and chemokines, and production of reactive oxygen species and increased the levels and activities of Kir 6.2, NF-κB, phosphorylated-Akt and mTOR, and the activation of JNK and p38-MAPK in keratinocytes. Inhibitors of c-JNK (SP600125) and p38-MAPK (SB203580) attenuated the lipoteichoic acid- or peptidoglycan-induced production of inflammatory mediators, the activation of the JNK and p38-MAPK, and the production of reactive oxygen species in keratinocytes. The results show that KATP channel blockers may reduce the bacterial component-stimulated production of inflammatory mediators in keratinocytes by suppressing the Toll-like receptor-2-mediated activation of the Akt, mTOR and NF-κB pathways, as well as JNK and p38-MAPK. The suppressive effect of KATP channel blockers appears to be achieved by the inhibition of reactive oxygen species production.Entities:
Keywords: 2′,7′-Dichlorofluorescin diacetate (Sigma-Aldrich Inc. PubChem CID 104913); 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (Sigma-Aldrich Inc. PubChem CID 64965); 5-Hydroxydecanoate; Akt, mTOR and NF-κB pathways; Bay 11-7085 ((2E)-3-[[4-(1,1-Dimethylethyl)phenyl]sulfonyl]-2-propenenitrile; Glibenclamide; Inflammatory mediator production; JNK and p38-MAPK; K(ATP) channel blockers; Keratinocytes; N-acetylcysteine(Sigma-Aldrich Inc. PubChem CID 12035); PubChem CID 1824; PubChem CID 3488; PubChem CID 5353432); Rapamycin (Sigma-Aldrich Inc. PubChem CID 5284616); SB203580 (Sigma-Aldrich Inc. PubChem CID 176155); SP600125 (Sigma-Aldrich Inc. PubChem Substance ID 24278395); Trolox (EMD-Calbiochem PubChem CID 40634)
Mesh:
Substances:
Year: 2017 PMID: 28923349 DOI: 10.1016/j.ejphar.2017.09.014
Source DB: PubMed Journal: Eur J Pharmacol ISSN: 0014-2999 Impact factor: 4.432